“…Similar findings have been previously attributed to SGLT-2 inhibitors due to glycosuria [ 60 ]. Mild volume depletion (presented with symptomatic hypotension or orthostatic hypotension, polyuria, dehydration, dizziness, vertigo, presyncope, thirst, and rarely orthostatic hypotension), weight loss, a reduction in SBP, the potential deterioration of renal function (increases in serum creatinine levels, decreases in the eGFR), acute kidney injury or failure, potential changes in hematocrit and hemoglobulin, liver function deterioration, diabetic ketoacidosis, and hypoglycemia can also be attributed to the pharmacology of the SGLT-2 inhibitor class [ 37 , 50 , 57 , 61 ], which causes osmotic diuresis, natriuresis, glucosuria, and caloric wasting [ 60 ]. For instance, in their study, Wilcox et al reported two cases, one with syncope attributed possibly to orthostatic hypotension and another presented with hypokalemia that required oral potassium chloride to be administered [ 39 ].…”